UY29903A1 - Dialurea para el tratamiento de la hipertension pulmonar - Google Patents

Dialurea para el tratamiento de la hipertension pulmonar

Info

Publication number
UY29903A1
UY29903A1 UY29903A UY29903A UY29903A1 UY 29903 A1 UY29903 A1 UY 29903A1 UY 29903 A UY29903 A UY 29903A UY 29903 A UY29903 A UY 29903A UY 29903 A1 UY29903 A1 UY 29903A1
Authority
UY
Uruguay
Prior art keywords
treatment
pulmonary hypertension
dialurea
fluorophenosi
trifluoromethylphenyl
Prior art date
Application number
UY29903A
Other languages
English (en)
Inventor
Dr Martina Klein
Dr Joachim Hutter
Dr Peter Sandner
Dr Hanna Tinel
Dr Bernd Riedl
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of UY29903A1 publication Critical patent/UY29903A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas para el tratamiento, prevención o control de hipertensión pulmonar que comprenden metilamida del ácido 4(4-(3-(4-cloro-3-trifluorometilfenil)-ureido)-3-fluorofenosi)-piridina-2-carboxílico, opcionalmente combinada con al menos un agente terapéutico adicional.
UY29903A 2005-11-10 2006-11-07 Dialurea para el tratamiento de la hipertension pulmonar UY29903A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05024509 2005-11-10
EP05027450 2005-12-15
EP06012234 2006-06-14

Publications (1)

Publication Number Publication Date
UY29903A1 true UY29903A1 (es) 2007-06-29

Family

ID=37622057

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29903A UY29903A1 (es) 2005-11-10 2006-11-07 Dialurea para el tratamiento de la hipertension pulmonar

Country Status (18)

Country Link
US (1) US20100035888A1 (es)
EP (1) EP1948170A1 (es)
JP (1) JP5084736B2 (es)
KR (1) KR20080067000A (es)
AR (1) AR057849A1 (es)
AU (1) AU2006312714A1 (es)
BR (1) BRPI0618522A2 (es)
CA (1) CA2628849A1 (es)
CR (1) CR9953A (es)
EC (1) ECSP088430A (es)
GT (1) GT200800058A (es)
IL (1) IL191178A0 (es)
NO (1) NO20082498L (es)
PE (1) PE20070806A1 (es)
SV (1) SV2009002900A (es)
TW (1) TW200733961A (es)
UY (1) UY29903A1 (es)
WO (1) WO2007054216A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (en) * 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
NZ626589A (en) * 2003-02-21 2016-01-29 Resmed Ltd Nasal assembly
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
PT1626714E (pt) * 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
ES2297490T3 (es) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
BRPI0515946A (pt) * 2004-09-29 2008-08-12 Bayer Healthcare Ag sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US8680124B2 (en) * 2007-01-19 2014-03-25 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
JP2011525503A (ja) * 2008-06-25 2011-09-22 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全を処置するためのジアリールウレア
CA2796744A1 (en) * 2010-04-17 2011-10-20 Bayer Healthcare Llc Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
MX2013003695A (es) 2010-10-01 2013-05-20 Bayer Ip Gmbh Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida.
US20140127295A1 (en) * 2011-03-14 2014-05-08 Cellworks Group, Inc Compositions, process of preparation of said compositions and method of treating inflammatory diseases
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
ATE386528T1 (de) * 2002-04-10 2008-03-15 Univ Virginia Commonwealth Kombination von glivec (sti571) mit einem cyclinabhängigen kinaseinhibitoren, ins besonders flavopiridol, zur behandlung von krebs
PT1626714E (pt) * 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
ES2297490T3 (es) * 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
WO2006091542A2 (en) * 2005-02-22 2006-08-31 Cedars-Sinai Medical Center Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier

Also Published As

Publication number Publication date
IL191178A0 (en) 2009-08-03
PE20070806A1 (es) 2007-09-29
KR20080067000A (ko) 2008-07-17
AR057849A1 (es) 2007-12-19
US20100035888A1 (en) 2010-02-11
BRPI0618522A2 (pt) 2011-09-06
EP1948170A1 (en) 2008-07-30
JP5084736B2 (ja) 2012-11-28
CA2628849A1 (en) 2007-05-18
TW200733961A (en) 2007-09-16
SV2009002900A (es) 2009-04-28
CR9953A (es) 2008-10-08
GT200800058A (es) 2010-02-23
AU2006312714A1 (en) 2007-05-18
NO20082498L (no) 2008-08-07
ECSP088430A (es) 2008-07-30
JP2009514910A (ja) 2009-04-09
WO2007054216A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
UY29903A1 (es) Dialurea para el tratamiento de la hipertension pulmonar
CU23815A3 (es) Diarilureas para el tratamiento de hipertensión pulmonar
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
CY1109307T1 (el) Χρηση αδαπαλενιου για τη θεραπεια δερματολογικων διαταραχων
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
NO20083836L (no) N-hydroksyakrylamidforbindelser
NO20090623L (no) Forbindelser for behandling av proliferative lidelser
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
BR112013021236A2 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
PE20081506A1 (es) Formulaciones de ansamicina
BRPI0807528A2 (pt) Composições lubrificantes pessoais complementares
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CL2007003189A1 (es) Compuestos derivados de indol y benzofurano; composicion farmaceutica; y uso para el tratamiento o la prevencion de la enfermedad de alzheimer.
NO20093542L (no) Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer
DOP2007000073A (es) Compuestos para tratar la hipertensión pulmonar
NO20076405L (no) Anvendelse av 24-nor-UDCA
ATE437988T1 (de) Neues imprägnierverfahren einer textiloberfläche
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
DOP2006000244A (es) Diarilurea para el tratamiento de hipertensión pulmonar
WO2009074498A8 (en) Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate
WO2007002093A3 (en) Ansamycin formulations and methods of use thereof

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160920